The firm is also targeting a new market for oral fluid-based tests for drugs of abuse, projecting future growth due to new federal regulations.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
By examining metagenomic data of bacterial species in a patient's gut, the researchers aim to improve diagnosis and long-term nutritional intervention and treatment.
The researchers said a microbiome-based test could expand the number of individuals who are screened for the disease.
At the Precision Medicine World Conference, researchers from Sanford Health, Providence Health, and Israel's Maccabi discussed their genomics programs.
The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.